Comparison between 0.1% Nepafenac and 1% Prednisolone Eye Drop in Postoperative Management Following Micro-incisional Cataract Surgery

Korean J Ophthalmol. 2021 Jun;35(3):188-197. doi: 10.3341/kjo.2020.0135. Epub 2021 Jun 4.

Abstract

Purpose: To compare the efficacy of 0.1% nepafenac and 1% prednisolone acetate eye drop in postoperative inflammation control in micro-incisional cataract surgery.

Methods: We conducted a prospective, randomized, comparative, single-blind study. All the patients underwent temporal 2.2-mm micro-incisional cataract surgery. They were randomized into two groups (group A and B). Group A received 0.1% nepafenac eye drops 4 times/day for 4 weeks and group B received 1% prednisolone acetate eye drops in tapering doses for 4 weeks after surgery. Both the groups received moxifloxacin 0.5% eye drops 4 times/day for 2 weeks. Patients were examined on 1st, 7th, and 30th postoperative days and parameters of postoperative inflammation were evaluated and noted at each visit.

Results: A total of 200 patients were enrolled in the study. However, five patients lost to follow up, group A had 97 and group B had 98 patients respectively. Results were statistically insignificant in terms of the difference in lid edema, conjunctival congestion, corneal edema, anterior chamber cells and flare between the two groups with p-values >0.05 for each parameter at each visit. However, the difference in mean central macular thickness between the groups was significant (205.713 ± 17.14 vs. 220.984 ± 32.83 in group A and B, respectively, p ≤ 0.001) at 1 month. Also, the mean pain score was significantly lower (p = 0.018) in the nepafenac group at day 7 of surgery.

Conclusions: Nepafenac is equally effective and non-inferior to prednisolone acetate in suppression and prevention of inflammation in postoperative period.

Keywords: Cataract; Inflammation; Macular edema; Nepafenac; Prednisolone acetate.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal*
  • Benzeneacetamides
  • Cataract*
  • Double-Blind Method
  • Humans
  • Ophthalmic Solutions
  • Phenylacetates
  • Postoperative Complications / prevention & control
  • Postoperative Period
  • Prednisolone / therapeutic use
  • Prospective Studies
  • Single-Blind Method

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Benzeneacetamides
  • Ophthalmic Solutions
  • Phenylacetates
  • nepafenac
  • Prednisolone